产品
编 号：F274515
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 216503-57-0
产品详情
生物活性：
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research.
体内研究：
Alemtuzumab (Campath-IH；0.5-5 mg/kg；腹腔注射；单剂量) 会导致外周血和淋巴器官中 B 和 T 淋巴细胞的剂量依赖性消耗。 Animal Model:hCD52 transgenic mice
Dosage:0.5-5 mg/kg
Administration:IP; a single dose
Result:Resulted in the dose-dependent depletion of B and T lymphocytes in the peripheral blood and lymphoid organs.
Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research.
体内研究：
Alemtuzumab (Campath-IH；0.5-5 mg/kg；腹腔注射；单剂量) 会导致外周血和淋巴器官中 B 和 T 淋巴细胞的剂量依赖性消耗。 Animal Model:hCD52 transgenic mice
Dosage:0.5-5 mg/kg
Administration:IP; a single dose
Result:Resulted in the dose-dependent depletion of B and T lymphocytes in the peripheral blood and lymphoid organs.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备